Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | HPGD | P15428 | 5/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3252698 | 0.83 | BCL2L1 (0.53) | ALDH1A1HPGDCHRNA7HDAC1HDAC3 | |
| SCHEMBL2895989 | 0.83 | ALDH1A1 (0.55) | ALDH1A1HPGDCHRNA7HSD17B10HDAC1 | |
| SCHEMBL15384380 | 0.83 | HPGD (0.55) | ALDH1A1HPGDCHRNA7HSD17B10HDAC1 | |
| SCHEMBL5125588 | 0.83 | HPGD (0.55) | ALDH1A1HPGDCHRNA7HSD17B10HDAC1 | |
| SCHEMBL25094033 | 0.81 | HDAC1 (0.56) | ALDH1A1HPGDCHRNA7HDAC1HDAC3 | |
| SCHEMBL2889381 | 0.81 | ALDH1A1 (0.54) | ALDH1A1HPGDCHRNA7HDAC1HDAC3 | |
| SCHEMBL6331448 | 0.81 | HPGD (0.54) | ALDH1A1HPGDCHRNA7HSD17B10HDAC1 | |
| SCHEMBL2897562 | 0.81 | HDAC3 (0.68) | ALDH1A1HPGDCHRNA7HDAC1HDAC3 | |
| SCHEMBL1091054 | 0.81 | HPGD (0.54) | ALDH1A1HPGDCHRNA7HDAC1HDAC3 | |
| SCHEMBL17858439 | 0.80 | HPGD (0.52) | ALDH1A1HPGDCHRNA7HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200055871-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF | Kineta Immuno-Oncology LLC | 2020-02-20 | — | — | US | disclosed |
| US-20200055871-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF | Kineta Immuno-Oncology LLC | 2020-02-20 | — | — | US | disclosed |
| WO-2020036574-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I' PATHWAY AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020036574-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I' PATHWAY AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020036812-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
| EP-1497278-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2010-05-26 | — | — | EP | disclosed |
| EP-1497278-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2010-05-26 | — | — | EP | disclosed |
| US-7550461-B2 | Benzofuran and benzothiophene compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550461-B2 | Benzofuran and benzothiophene compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550461-B2 | Benzofuran and benzothiophene compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1497278-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20030225053-A1 | Compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003087085-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055871-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF | RARB, RARG, RARA | ALDH1A1 72/4885HPGD 1372/4885CHRNA7 2800/4885 |
| US-20030225053-A1 | Compounds useful in treating cytokine mediated diseases | IL6, IL1A, IL1B | ALDH1A1 336/4885HPGD 326/4885CHRNA7 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.